Company / strategic investorRegistered location :Baar

HBM BioVentures AGDeclared Swiss shareholdings

HBM BioVentures AG: 4 Swiss companies with a declared holding, including Basilea Pharmaceutica AG, Allschwil, Kuros Biosciences AG, HBM Healthcare Investments AG. Latest filing: 17.02.2012.

Disclosure tracking · company alerts with Pro

Estimated value (CHF): …
Swiss companies held: 4
Largest position: 20,11 %; Basilea Pharmaceutica AG, Allschwil
12-month trend: Not determinable; 0 rate rises · 0 rate falls
Latest filing: 17.02.2012; Active since 2004

Declared Swiss portfolio

Latest declared rate per company

Sector allocation

Share of companies held

Basilea Pharmaceutica AG, Allschwil

20,11 %17.02.2012

Kuros Biosciences AG

6,6 %25.03.2004

HBM Healthcare Investments AG

5 %03.11.2011

Newron Pharmaceuticals S.p.A.

2,98 %21.11.2009

How to read these figures?

Rates come from the 28 official filings published by SIX Exchange Regulation. A filing is only required when a threshold is crossed (3, 5, 10, 15, 20, 25, 33⅓, 50, 66⅔%): the actual position may have changed since.

Estimated value = shares held per the latest filing × latest CHF closing price. It is an indicative order of magnitude: the position may have changed without a new threshold being crossed, and holdings without a share count or a CHF price are not valued. Each company's mini-chart traces the successive declared rates.

This profile shows only what the declarant published. No external data is added to it.

Group structure

Shareholding disclosures are often filed jointly by several entities of the same group. The registry links them together: "Controls" lists the group entities declared alongside this shareholder, "Controlled by" the head entities. The figure is the number of joint disclosures, followed by the date of the most recent one.

Show group structure3 controlled by · 1 controls

Controlled by

Group entities that file jointly with this shareholder as its head.

HBM BioVentures Cayman Ltd9 · 21.05.2008
HBM BioVentures Ltd. Cayman4 · 10.01.2008
NMT New Medical Technologies1 · 13.02.2003

Controls

Group entities linked to this shareholder in joint disclosures.

HBM BioVentures Cayman Ltd5 · 17.02.2012

This mapping reflects observed disclosures; it does not necessarily indicate permanent legal control.

Disclosure behaviour

Upward and downward threshold crossings show direction, without measuring daily trades below legal thresholds.

90 days · Upward crossings

visible history: 14

90 days · Downward crossings

visible history: 0

First disclosure: 25.03.2004Last disclosure: 17.02.2012

Nature of disclosed positions

Derivatives, sale positions or lending may indicate a more complex strategy than a long equity holding.

Equity holdings

Declared Swiss portfolio

Sector allocation

Group structure

Controlled by

Controls

Disclosure behaviour

Nature of disclosed positions

Latest shareholding disclosures

Follow HBM BioVentures AG’s disclosures

Management purchases in this portfolio

Common questions

Explore further

Recent insider purchases

Insider barometer